Navigation Links
HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Date:6/12/2012

CHARLOTTESVILLE, Va., June 12, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, announced today that they have published a key Review article entitled, Organotypic systems in drug metabolism and toxicity: challenges and opportunities, in Expert Opin. Drug Metab. Toxicol. Authored by Ajit Dash, MD, PhD and HemoShear co-founders Brett R. Blackman, PhD and Brian R. Wamhoff, PhD, this Expert Opinion examines the various approaches to recreating meaningful human biology on the bench and traces the evolution of organotypic systems while discussing intrinsic challenges and opportunities that lie ahead. Furthermore, they cite literature that is the foundation of several biotechnology research companies addressing this issue and discuss major government-funded initiatives to aid the development of these systems.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

"High-throughput screening cell-based tools still serve a purpose in compound screening campaigns, but they continue to fail in predicting in vivo response for important and costly pipeline decisions," said Dr. Dash, Director of HemoShear's Liver Surrogate Systems Division. "Further, the limitations of animal models in predicting human safety or drug efficacy continue to negatively impact drug companies' confidence as they make important decisions about whether to enter human clinical trials."

"Our vision as a company is to develop meaningful human-relevant systems so that we can help our biopharmaceutical partners make more meaningful decisions in their pre-clinical pipelines, greatly reducing the risk in their portfolio," said Dr. Wamhoff. "Initial results in our vascular and liver surrogate systems indicate that we can recreate human in vivo biology and response on the bench, which is extremely exciting! Continued development and validation of these systems and disease systems is important to our partners. The science is groundbreaking and the data human-relevant.  We really are thinking about drug discovery from the human perspective."

About HemoShear, LLC
HemoShear LLC is a biotechnology research company that combines its scientific expertise with its proprietary platform technology in research collaborations with pharmaceutical companies to accelerate drug discovery and development. HemoShear has expertise in the areas of human and animal biology, bioinformatics and molecular profiling for target identification and validation, cell-signaling pathway analysis, sophisticated methods to quantify target genes and proteins, assessment of molecular pharmacology, and methods to determine mechanisms of action for drug efficacy and safety.

HemoShear's technology platform can be adapted to replicate the biology of human or animal organ systems in both healthy and disease-prone states by applying physiologically accurate hemodynamic forces to primary cell cultures.  HemoShear is currently collaborating with several large pharmaceutical companies on programs that span the drug discovery and development spectrum.  HemoShear is a privately held company located in Charlottesville, Virginia.  To learn more about HemoShear and our research, please visit our website at www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
4. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
5. Delcath Systems, Inc. Secures $20 Million Credit Facility
6. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
9. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
10. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
11. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive who ... global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and ... and building successful businesses in the sector and has worked in ... North America . ... Educated at the University of Edinburgh (Dental Surgery), ...
(Date:1/16/2017)... Analytics 4 Life (A4L), a machine intelligence company developing ... @ Toronto , one of Johnson ... in the space, A4L has access to a rich ... JLABS @ Toronto ... flexible environment for start-up companies pursuing new technologies and ...
(Date:1/16/2017)... NASHVILLE, Tenn. , Jan. 16, 2017  Cumberland ... addition of Kenneth J. Krogulski , CFA to ... Chief Executive Officer of Berkshire Asset Management LLC ... Berkshire, a 30-year-old independent SEC registered investment advisory firm ... Krogulski has over 37 years, experience in security analysis ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Aesthetic Surgery Journal , the official journal of The American Society for Aesthetic ... retraction surgery. The procedure is designed to correct drooping, retracted lower eyelids, which ...
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
(Date:1/15/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... services. Albertsons Companies is the largest national food and drug chain with ... Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to meeting national standards ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go this Valentine's Day? ... your door for a romantic, lobster feast in the comfort of your own home. ... The dinners will be featured until February 15th, 2017. , Romantic Dinner one ...
Breaking Medicine News(10 mins):